Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2004

View Archived Issues

Shionogi researchers claim iNOS inhibitors and their therapeutic use

New leucomycin A7 derivatives and their use in Gram-positive bacterial infections

Abbott presents new PDE4 and TNF-alpha production inhibitors

Novel MCH antagonists in early development at Aventis

Novel glycogen phosphorylase inhibitors developed by Aventis team

New vanilloid VR1 antagonists and their use in pain, urinary incontinence, etc.

New beta-lactamase-resistant carbapenems discovered at Sankyo

Pyrazole-based antiplatelet agents newly developed at Daiichi

Selective inhibitors of PKB/Akt designed at Astex

ABP-309: a second-generation VEGFR tyrosine kinase inhibitor with a promising preclinical profile

First clinical results reported for AMG-706 in patients with advanced tumors

Inhibition of SOD1 via copper depletion results in inhibition of angiogenesis

Novel VEGFR2/PDGFR kinase inhibitor with antitumor and antiangiogenic activity presented by Bayer

Pharmacyclics identifies potential development candidate from a series of sapphyrin derivatives

Recordati to market prulifloxacin in Spain

Millennium submits supplemental NDA for Velcade

Bayer inlicenses Seattle Genetics' ADC technology

New approvals for Enbrel

L-BLP-25 liposome vaccine receives fast track status for NSCLC

Phase I cleared to begin for CDA-1 for C. difficile associated diarrhea

Genaera receives SBIR grant for development of trodusquemine

New phase II study for M-40403 in cancer pain

Enrollment completed in phase IIb African sleeping sickness trial of DB-289

New dosing option of Omnicef approved for pediatric use

Expanded phase II trial for squalamine opens enrollment

Epimmune plans phase II study of EP-2101 cancer vaccine

Exelixis to acquire X-Ceptor Therapeutics

Merck voluntarily withdraws Vioxx

New data on the efficacy of onercept in active Crohn's disease

Update on the efficacy of ABT-874 in active Crohn's disease

Prous Science launches new enhanced version of LifeSciChannel.com

Uriach selects UR-14048 for further development for parenteral treatment of acute pain

NP-031112 and NP-00111 demonstrate neuroprotectant effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...